Necrotizing Meningoencephalitis

Necrotizing meningoencephalitis (NME) is a severe, non-suppurative inflammatory disease of the central nervous system (CNS) primarily affecting the brain and meninges. It is characterized by multifocal to diffuse necrosis of the cerebral cortex and subcortical white matter, with a prominent mononuclear inflammatory infiltrate. The disease is most commonly recognized in small breed dogs, particularly Pugs, Maltese, and Chihuahuas, and is considered an immune-mediated or possibly autoimmune disorder. NME is one of several non-infectious inflammatory brain diseases (NIBD) of dogs, which also include granulomatous meningoencephalomyelitis (GME) and necrotizing leukoencephalitis (NLE). The condition is rapidly progressive and often fatal without aggressive immunosuppressive therapy. Clinical signs reflect diffuse cerebral involvement, including seizures, behavioral changes, and visual deficits. Diagnosis is challenging and often requires advanced imaging (MRI) and cerebrospinal fluid (CSF) analysis, with definitive diagnosis only via histopathology. Early recognition and treatment may prolong survival, but the prognosis remains guarded to poor.

The exact etiology of NME is unknown, but a strong genetic predisposition is suspected, particularly in certain breeds. An immune-mediated or autoimmune pathogenesis is widely supported, with evidence of T-cell-mediated inflammation and the presence of autoantibodies against glial cells. Viral triggers have been proposed, but no consistent infectious agent has been isolated. Molecular mimicry or dysregulated immune responses to environmental antigens may play a role. Genetic studies have identified associations with major histocompatibility complex (MHC) class II alleles in affected breeds, suggesting a heritable component. Environmental factors, such as vaccination or stress, have been hypothesized as triggers, but definitive evidence is lacking. The disease is not contagious and shows no sex predilection, although some studies suggest a higher incidence in females.

NME is primarily a disease of small breed dogs, with a marked predilection for Pugs, Maltese, and Chihuahuas. Other breeds, including Yorkshire Terriers, Papillons, and Shih Tzus, may also be affected. The age of onset is typically young to middle-aged, ranging from 6 months to 7 years, with a median around 2-3 years. There is no clear sex predilection, though some reports indicate a slight female predominance. The disease is worldwide in distribution, but breed-specific prevalence varies geographically. In Pugs, the incidence is estimated to be around 1-2% in some populations. The condition is sporadic, with no seasonal or environmental clustering. Genetic factors are significant, as evidenced by familial clustering and breed-specific susceptibility. No infectious etiology has been confirmed, and the disease is not zoonotic.

The pathophysiology of NME involves a dysregulated immune response targeting the central nervous system. Histopathologically, there is multifocal to diffuse necrosis of the cerebral cortex and subcortical white matter, with infiltration of lymphocytes (predominantly T cells) and macrophages. The inflammatory process leads to disruption of the blood-brain barrier, vasogenic edema, and neuronal death. The exact antigenic target is unknown, but autoantibodies against glial fibrillary acidic protein (GFAP) and other neural antigens have been detected in some cases. The inflammatory cascade involves activation of microglia, release of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), and recruitment of peripheral immune cells. The necrotizing nature of the lesions distinguishes NME from other inflammatory brain diseases. The disease progresses rapidly, with extensive parenchymal destruction leading to severe neurological deficits and often death. Secondary complications include increased intracranial pressure, herniation, and aspiration pneumonia due to seizures or altered mentation.

The primary predisposing factor for NME is genetic susceptibility, particularly in certain breeds. Specific MHC class II haplotypes have been associated with increased risk in Pugs and Maltese. Age is a significant factor, with young adult dogs most commonly affected. Stress, vaccination, or concurrent infections may trigger the onset of clinical signs in genetically susceptible individuals, though this is not well-established. Environmental factors such as exposure to toxins or dietary factors have been speculated but not proven. There is no evidence of sex predisposition, but some studies suggest a slight female predominance. Immunosuppression or immune dysregulation due to other diseases may also increase susceptibility. Overall, the disease is considered idiopathic, with a strong genetic component.

Clinical signs of NME are typically acute to peracute in onset and rapidly progressive. They reflect diffuse cerebral involvement and may include: seizures (generalized or focal), which are often the first sign; behavioral changes such as depression, lethargy, or aggression; circling; head pressing; visual deficits (central blindness); proprioceptive deficits; ataxia; and altered mentation (stupor or coma). Cranial nerve deficits may be present, including facial nerve paralysis or anisocoria. Fever is uncommon. In advanced stages, signs of increased intracranial pressure, such as papilledema, bradycardia, and respiratory abnormalities, may occur. The disease can progress to death within days to weeks without treatment. Some dogs may have a more chronic course with waxing and waning signs. Neurological examination typically reveals forebrain signs, with normal spinal reflexes unless there is concurrent spinal cord involvement (rare).

Differential diagnoses for NME include other non-infectious inflammatory brain diseases such as granulomatous meningoencephalomyelitis (GME) and necrotizing leukoencephalitis (NLE). GME often presents with multifocal CNS signs, and MRI may show contrast-enhancing lesions, but histopathology is needed for definitive differentiation. NLE primarily affects the white matter and is more common in Yorkshire Terriers. Infectious causes include canine distemper virus (CDV), rabies, toxoplasmosis, neosporosis, cryptococcosis, and bacterial meningitis. These can be ruled out with serology, PCR, and CSF analysis. Neoplastic conditions such as primary brain tumors (e.g., glioma, meningioma) or metastatic disease may mimic NME, but MRI characteristics and CSF cytology can help differentiate. Vascular events such as ischemic stroke or hemorrhage may cause acute onset of signs, but imaging findings differ. Metabolic encephalopathies (e.g., hepatic encephalopathy, hypoglycemia) should also be considered, but they typically have systemic signs and laboratory abnormalities.

The diagnostic approach to suspected NME involves a stepwise algorithm: 1) Complete history and thorough neurological examination to localize the lesion to the forebrain. 2) Baseline laboratory tests (CBC, serum biochemistry, urinalysis) to rule out systemic diseases. 3) Advanced imaging, preferably MRI of the brain, which is the most sensitive modality. MRI findings in NME include multifocal, asymmetric T2-hyperintense lesions in the cerebral cortex and subcortical white matter, with variable contrast enhancement and mass effect. 4) CSF analysis, which typically shows mononuclear pleocytosis (lymphocytes and macrophages) with elevated protein, but may be normal in some cases. 5) Infectious disease testing (e.g., CDV titers, Toxoplasma/Neospora titers, Cryptococcus antigen) to rule out infectious causes. 6) If imaging and CSF are inconclusive, brain biopsy may be considered for definitive diagnosis, but it is invasive and not always feasible. 7) Response to immunosuppressive therapy can support the diagnosis. Definitive diagnosis requires histopathology, which is often performed post-mortem.

Routine laboratory findings in NME are often unremarkable. Complete blood count (CBC) may show mild leukocytosis or eosinophilia, but is usually within normal limits. Serum biochemistry is typically normal, though mild elevations in liver enzymes may occur due to stress or drug therapy. Cerebrospinal fluid (CSF) analysis is the most important laboratory test: it typically reveals increased protein concentration (often >50 mg/dL) and mononuclear pleocytosis (lymphocytes and macrophages), with cell counts ranging from 10 to several hundred cells/µL. In some cases, CSF may be normal, especially in early or chronic stages. PCR for infectious agents (e.g., CDV, Toxoplasma, Neospora) on CSF is negative. Serological tests for infectious diseases are negative. Autoantibody testing (e.g., anti-GFAP antibodies) is not widely available but may be supportive. Other biomarkers such as S100B or neuron-specific enolase are not routinely used.

Magnetic resonance imaging (MRI) is the imaging modality of choice for NME. Typical findings include multifocal, asymmetric T2-weighted and FLAIR hyperintense lesions in the cerebral cortex, subcortical white matter, and sometimes the thalamus or brainstem. Lesions may be poorly marginated and show variable contrast enhancement, often with a gyral pattern. Mass effect may be present, leading to midline shift or herniation. In chronic cases, areas of necrosis may appear as cystic cavities. Computed tomography (CT) is less sensitive but may show hypodense lesions with contrast enhancement. Radiography is not useful for brain imaging. Advanced imaging techniques such as diffusion-weighted imaging (DWI) may show restricted diffusion in areas of necrosis. MRI is also useful to rule out other causes such as neoplasia or vascular events.

Cytological examination of CSF may show a mixed mononuclear population, predominantly small lymphocytes and macrophages, with occasional plasma cells and neutrophils. The presence of reactive lymphocytes or atypical cells is uncommon. Histopathology of brain tissue is the gold standard for diagnosis. Grossly, affected areas may appear softened, discolored, or cavitated. Microscopically, there is multifocal to diffuse necrosis of the cerebral cortex and subcortical white matter, with infiltration of lymphocytes (T cells) and macrophages. Perivascular cuffing is prominent. The inflammatory infiltrate is non-suppurative, and there is often astrogliosis and microgliosis. Special stains (e.g., Luxol fast blue) may show myelin loss. Immunohistochemistry can confirm T-cell predominance. The necrotizing nature of the lesions distinguishes NME from GME, which typically has granulomatous inflammation with epithelioid macrophages.

Treatment of NME is primarily immunosuppressive and symptomatic. The mainstay is high-dose corticosteroids, such as prednisone, at immunosuppressive doses (1-2 mg/kg/day PO, divided q12h). In severe cases, pulse therapy with methylprednisolone sodium succinate (15-30 mg/kg IV q6-8h for 24-48 hours) may be used initially. Additional immunosuppressive agents are often added to reduce steroid side effects and improve efficacy. Commonly used drugs include cytosine arabinoside (Ara-C) at 50 mg/m² SC q12h for 2 days, repeated every 3 weeks; leflunomide (4 mg/kg PO q24h); or mycophenolate mofetil (10-20 mg/kg PO q12h). Cyclosporine (5-10 mg/kg PO q12h) may also be used. Anticonvulsant therapy is essential for seizure control, typically with phenobarbital (2.5-5 mg/kg PO q12h) or levetiracetam (20 mg/kg PO q8h). Supportive care includes intravenous fluids, nutritional support, and nursing care for recumbent patients. In cases of increased intracranial pressure, mannitol (0.5-1 g/kg IV over 20 minutes) may be administered. Radiation therapy has been reported to be beneficial in some cases, but is not widely available. Surgery is not indicated except for biopsy.

The prognosis for NME is generally poor to guarded. Without treatment, the disease is rapidly progressive and fatal within weeks to months. With aggressive immunosuppressive therapy, some dogs may achieve remission and survive for months to years, but the median survival time is often reported as 3-6 months. Factors associated with a worse prognosis include severe neurological deficits, lack of response to initial therapy, and the presence of brainstem involvement. Dogs that respond to treatment within the first few weeks may have a better outcome. However, relapses are common, and long-term survival beyond 1-2 years is rare. The disease is ultimately fatal in most cases due to progressive neurological deterioration or complications such as aspiration pneumonia or status epilepticus. Early diagnosis and aggressive treatment may improve quality of life and extend survival, but a cure is not possible.

Follow-up for dogs with NME should be frequent and structured. Initially, re-evaluation should occur every 2-4 weeks to assess response to therapy and adjust drug dosages. Serial neurological examinations are essential to monitor for improvement or progression. Blood pressure and urine analysis should be monitored regularly due to corticosteroid therapy. Serum biochemistry and CBC should be checked periodically to monitor for drug side effects (e.g., hepatotoxicity from phenobarbital, bone marrow suppression from Ara-C). CSF analysis may be repeated to assess response, but is not always necessary. MRI may be repeated if clinical signs worsen or to evaluate for disease progression. Long-term management involves tapering immunosuppressive drugs to the lowest effective dose, often over several months. Owners should be educated on the signs of relapse and the importance of strict medication compliance. Regular veterinary visits every 3-6 months are recommended for maintenance.

Pearls: 1) NME should be a top differential in any young small breed dog (especially Pug, Maltese, Chihuahua) presenting with seizures and forebrain signs. 2) MRI is the most sensitive diagnostic tool; CSF may be normal in up to 20% of cases. 3) Early aggressive immunosuppression with a combination of corticosteroids and a second agent (e.g., Ara-C) may improve outcomes. 4) Seizure control is critical; use levetiracetam if phenobarbital is not tolerated. 5) Always rule out infectious causes before starting immunosuppressive therapy. Pitfalls: 1) Delaying immunosuppressive therapy while awaiting definitive diagnosis can be fatal. 2) Using low-dose corticosteroids (anti-inflammatory) is ineffective and may allow disease progression. 3) Failing to monitor for steroid side effects (e.g., iatrogenic hyperadrenocorticism, GI ulceration). 4) Discontinuing immunosuppressive drugs too quickly can lead to relapse. 5) Assuming a normal CSF rules out NME.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Prednisone: 1-2 mg/kg PO q12h initially, then taper over 6-12 months. For pulse therapy, methylprednisolone sodium succinate: 15-30 mg/kg IV q6-8h for 24-48 hours. 2) Cytosine arabinoside (Ara-C): 50 mg/m² SC q12h for 2 consecutive days, repeated every 3 weeks. Monitor CBC for myelosuppression. 3) Leflunomide: 4 mg/kg PO q24h; adjust dose based on clinical response and side effects. 4) Mycophenolate mofetil: 10-20 mg/kg PO q12h; may cause GI upset. 5) Cyclosporine: 5-10 mg/kg PO q12h; monitor trough levels if possible. 6) Phenobarbital: 2.5-5 mg/kg PO q12h; therapeutic range 15-45 µg/mL. 7) Levetiracetam: 20 mg/kg PO q8h; adjust for renal impairment. 8) Mannitol: 0.5-1 g/kg IV over 20 minutes for increased intracranial pressure. All immunosuppressive drugs require careful monitoring for side effects and drug interactions. Corticosteroids should be tapered slowly to avoid adrenal crisis.

Evidence for the treatment of NME is largely based on retrospective studies and expert opinion. A landmark study by Talarico and Schatzberg (2010) reviewed the clinical features and outcomes of NME in Pugs, reporting a median survival of 93 days with corticosteroid therapy alone, but longer survival with combination therapy. Another study by Lowrie et al. (2016) compared different immunosuppressive protocols and found that the addition of Ara-C to prednisone improved survival times. ACVIM consensus statements on the diagnosis and treatment of non-infectious inflammatory brain diseases (2016) recommend a combination of corticosteroids and a second immunosuppressive agent. There are no prospective randomized controlled trials due to the rarity of the disease. Recent research has focused on genetic markers and immunopathogenesis, with studies identifying MHC class II associations. Overall, the evidence base is limited, and treatment is largely empirical, but early aggressive therapy is associated with improved outcomes.